Literature DB >> 25039313

The suppressive function of human CD8(+) iTregs is inhibited by IL-1β and TNFα.

U Bjarnadottir1, A L Lemarquis, S Halldorsdottir, J Freysdottir, B R Ludviksson.   

Abstract

CD8(+) Tregs display an immunoregulatory activity and may play an essential role in the immunopathology of several diseases. Therefore, their therapeutic potential is exquisite and further studies on their differentiation and function are essential. The aim of this study was to evaluate the role of the innate immune system in CD8(+) iTreg differentiation and function. Naive human CD8(+) CD25(-) CD45RA(+) T cells were cultured in Treg-inducing conditions with or without IL-1β, TNFα or monocyte-derived dendritic cells (DCs). The differentiation of CD8(+) CD127(-) CD25(hi) FoxP3(hi) -induced Tregs (CD8(+) iTregs) is dependent on TGF-β1 and IL-2, which had synergistic effect upon their differentiation. CD8(+) iTregs were also induced in a coculture with allogeneic mature DCs (mDCs). The CD8(+) iTregs suppressive function was confirmed, which was diminished in the presence of IL-1β and TNFα. The IL-1β-prevented suppressive function was associated with reduced secretion of IL-10 and IFNγ, whereas the presence of TNFα did not affect their secretion. Furthermore, the presence of TNFα reduced IL-10 and TGF-β1 secretion by CD8(+) iTregs, whereas only IL-10 secretion was decreased by IL-1β. Together, these results suggest that IL-1β and TNFα prevent IL-2- and TGF-β1-driven CD8(+) iTregs suppressive function in human T cells. Such pro-inflammatory innate immune response possibly mediates its negative tolerogenic effect through reduced IFNγ-, IL-10- and TGF-β1-driven mechanism.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25039313     DOI: 10.1111/sji.12212

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  7 in total

1.  Maternal CD8+ T-cell depletion alleviates intrauterine inflammation-induced perinatal brain injury.

Authors:  Jun Lei; Li Xie; Hongxi Zhao; Candice Gard; Julia L Clemens; Michael W McLane; Mia C Feller; Maide Ozen; Christopher Novak; Wael Alshehri; Nader Alhejaily; Yahya Shabi; Jason M Rosenzweig; Andrea Facciabene; Irina Burd
Journal:  Am J Reprod Immunol       Date:  2017-12-04       Impact factor: 3.886

Review 2.  Regulatory T Cells in SLE: Biology and Use in Treatment.

Authors:  Sophia Giang; Antonio La Cava
Journal:  Curr Rheumatol Rep       Date:  2016-11       Impact factor: 4.592

3.  CDDO-Me Alters the Tumor Microenvironment in Estrogen Receptor Negative Breast Cancer.

Authors:  Michael S Ball; Rajan Bhandari; Gretel M Torres; Viktor Martyanov; Mohamed A ElTanbouly; Kim Archambault; Michael L Whitfield; Karen T Liby; Patricia A Pioli
Journal:  Sci Rep       Date:  2020-04-16       Impact factor: 4.379

Review 4.  Description of CD8+ Regulatory T Lymphocytes and Their Specific Intervention in Graft-versus-Host and Infectious Diseases, Autoimmunity, and Cancer.

Authors:  Martha R Vieyra-Lobato; Jorge Vela-Ojeda; Laura Montiel-Cervantes; Rubén López-Santiago; Martha C Moreno-Lafont
Journal:  J Immunol Res       Date:  2018-08-05       Impact factor: 4.818

Review 5.  Future prospects for CD8+ regulatory T cells in immune tolerance.

Authors:  Léa Flippe; Séverine Bézie; Ignacio Anegon; Carole Guillonneau
Journal:  Immunol Rev       Date:  2019-10-08       Impact factor: 12.988

6.  Association between aqueous humor cytokines and postoperative corneal endothelial cell loss after Descemet stripping automated endothelial keratoplasty.

Authors:  Tatsu Okabe; Wataru Kobayashi; Takehiro Hariya; Shunji Yokokura; Toru Nakazawa
Journal:  PLoS One       Date:  2021-12-16       Impact factor: 3.240

7.  Nanoparticles Engineered as Artificial Antigen-Presenting Cells Induce Human CD4+ and CD8+ Tregs That Are Functional in Humanized Mice.

Authors:  Sophia Giang; David A Horwitz; Sean Bickerton; Antonio La Cava
Journal:  Front Immunol       Date:  2021-05-26       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.